CN103893741A - Medicine composition for treating rhinitis - Google Patents
Medicine composition for treating rhinitis Download PDFInfo
- Publication number
- CN103893741A CN103893741A CN201410125537.0A CN201410125537A CN103893741A CN 103893741 A CN103893741 A CN 103893741A CN 201410125537 A CN201410125537 A CN 201410125537A CN 103893741 A CN103893741 A CN 103893741A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- active peptides
- small active
- essence
- chlorhexidine gluconate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a medicine composition for treating rhinitis. The medicine composition for treating rhinitis comprises the following constituents: micromolecular active peptide, chlorhexidine gluconate, glycerol, hydrogenated castor oil, mint essence and fragrant rice essence. The medicine composition disclosed by the invention is used as a spray, high in bacteriostatic action, capable of inhibiting bacteria such as staphylococcus aureus, candida albicans and escherichia coli, suitable for cleanliness and disinfection for nasal cavity, remarkable in effects on people with nasal obstruction, turbid nasal discharge, sneezing, headache, hyposmia, mycteroxerosis and the like due to acute and chronic rhinitis, allergic rhinitis, nasosinusitis, cold and the like.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, relate in particular to a kind of pharmaceutical composition for the treatment of rhinitis.
Background technology
Rhinitis is the inflammation of the bronchia mucosal that caused by antibacterial, virus, allergen, various physical and chemical factor and some systemic disease, and its basic reason is to have caused increasing of the cell number such as eosinophilic granulocyte, mastocyte in bronchia mucosal tissue.In air quality today worse and worse, the incidence probability of rhinitis is also increasing.Various virus, antibacterial is accompanied by airborne dust and is breathed the nasal cavity inside of arriving us, be attached on bronchia mucosal, make nasal mucosa occur the symptom such as inflammation, edema, therefore will find a kind of medicine that can clean nasal cavity, prevention and treatment rhinitis is the problem that needs most at present solution.
Research discovery, the small active peptides being made up of 2-4 aminoacid, not only can directly enter cell by cell membrane and improve repair cell, can also be the antibody of immune system manufacture to antibacterium and infection, improves body's immunity.Now small active peptides is applied to the nasal cavity of pathological changes, can utilizes the feature of small active peptides to directly act on diseased region, fundamentally realize the object of Prevention rhinitis.
At present, the report of the existing application in rhinitis there are no small active peptides.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of rhinitis.
Further, the object of the present invention is to provide a kind of externally-applied medicinal composition for the treatment of rhinitis.
Further, the object of the present invention is to provide a kind of externally-applied medicinal composition that not only can clean nasal cavity inside but also can prevent and treat rhinitis.
The constituent of pharmaceutical composition of the present invention take mass volume ratio as:
Small active peptides 1.0%～10.0%, chlorhexidine gluconate 0.1%～1.0%, glycerol 10%～20%,
Castor oil hydrogenated 0.1%～2.0%, Mint Essence 0.005%～0.015%, scented rice essence 0.01%～0.1%.Preferably, the constituent of pharmaceutical composition of the present invention take mass volume ratio as:
Small active peptides 2.0%～8.0%, chlorhexidine gluconate 0.2%～0.6%, glycerol 13%～18%,
Castor oil hydrogenated 0.5%～0.15%, Mint Essence 0.01%～0.015%, scented rice essence 0.03%～0.07%.Further, preferably, the constituent of pharmaceutical composition of the present invention take mass volume ratio as:
Small active peptides 3.0%～5.0%, chlorhexidine gluconate 0.3%～0.5%, glycerol 15%～18%,
Castor oil hydrogenated 0.6%～1.0%, Mint Essence 0.01%～0.013%, scented rice essence 0.03%～0.05%.Further, the optimum constituent of pharmaceutical composition of the present invention take mass volume ratio as:
Small active peptides 3.0%, chlorhexidine gluconate 0.45%, glycerol 15%, castor oil hydrogenated 1.0%, Mint Essence 0.01%, scented rice essence 0.05%.
Pharmaceutical composition of the present invention is achieved through the following technical solutions:
1. in the small active peptides of formula ratio, add corresponding chlorhexidine gluconate, glycerol and castor oil hydrogenated, heated and stirred stops heating after making it to dissolve and mixing.
2. to appropriate purified water in the mixture obtaining in step 1, thing temperature to be mixed adds Mint Essence and scented rice essence after dropping to 20 ℃～40 ℃, after stirring and evenly mixing, cross 0.45 μ m microporous filter membrane, gets filtrate.
3. to certain volume, carry out fill to adding purified water in the filtrate obtaining in step 2, every bottle of 15ml, after electromagnetic induction sealing, at 95 ℃, moist heat sterilization 30 minutes, obtains the pharmaceutical composition described in the present invention.
Small active peptides of the present invention derives from American-cockroach-extract, and its preparation process is:
Take periplaneta americana, add alcohol reflux 2-3 time of 70-90%, add respectively 8 times, 6 times, 6 times at every turn, filter decompression filtrate recycling ethanol.Be recycled to without ethanol taste, concentrated solution 2-10 ℃ of cold preservation 24-72 hour, sucks upper strata oils and fats with filter paper, subnatant is centrifugal, centrifugal liquid concentrating under reduced pressure, dry, pulverizing, be American-cockroach-extract, in every gram of extract, contains small active peptides more than 160mg.
Pharmaceutical composition of the present invention is to directly act on nasal cavity with aerosol apparatus.
Pharmaceutical composition of the present invention can be used for the cleaning-sterilizing of nasal cavity.
Pharmaceutical composition of the present invention has stronger bacteriostasis.
Pharmaceutical composition of the present invention is applicable to the crowds such as nasal obstruction that acute or chronic rhinitis, allergic rhinitis, sinusitis, flu etc. cause, watery nasal discharge, rhinocnesmus, sneeze, headache, hyposmia, dry nasal cavity.
Pharmaceutical composition of the present invention, can significantly reduce rhinitis and cause the eosinophilic granulocyte's number in bronchia mucosal tissue, and small active peptides in American-cockroach-extract in pharmaceutical composition of the present invention can permeate through cell membranes enter in cell, impaired cell in improvement and reparation bronchia mucosal, improve the immunocompetence of body, reach the effect of clean, prevention and treatment rhinitis with this.
By the following specific examples further illustrate the invention, but be not limited to the present invention.
The specific embodiment
Embodiment 1
By 0.45% chlorhexidine gluconate, 15% glycerol and 1.0% castor oil hydrogenated join in 3.0% small active peptides, agitating heating is dissolved, after mix homogeneously, stop adding after heating the purified water of 800ml, in the time that temperature is down to 25 ℃, add 0.01% Mint Essence and 0.05% scented rice essence, after stirring and evenly mixing, cross 0.45 μ m microporous filter membrane, filtrate adds after purified water is supplemented to 1000ml carries out fill, every bottle of 15ml, after electromagnetic induction sealing, at 95 ℃, moist heat sterilization 30 minutes, to obtain final product.
The preparation method of above-mentioned small active peptides is:
Take the dry polypide 1000g of periplaneta americana, add 90% alcohol reflux 3 times, add respectively 8 times, 6 times, 6 times at every turn, filter decompression filtrate recycling ethanol.Be recycled to without ethanol taste, 10 ℃ of cold preservations of concentrated solution 48 hours, suck upper strata oils and fats with filter paper, subnatant is centrifugal, and centrifugal liquid concentrating under reduced pressure, dry, pulverizing, be American-cockroach-extract, and the small active peptides wherein containing in every gram of extract is 196mg.
Embodiment 2
By 0.3% chlorhexidine gluconate, 15% glycerol and 0.6% castor oil hydrogenated join in 3.0% small active peptides, and agitating heating is dissolved, after mix homogeneously, stop adding 1000ml purified water after heating, in the time that temperature is down to 40 ℃, add 0.01% Mint Essence and 0.03% scented rice essence, after stirring and evenly mixing, cross 0.45 μ m microporous filter membrane, filtrate adds after purified water is supplemented to 2000ml carries out fill, every bottle of 15ml, after electromagnetic induction sealing, at 95 ℃, moist heat sterilization 30 minutes, to obtain final product.
The preparation method of above-mentioned small active peptides is:
Take periplaneta americana 2000g, add 80% alcohol reflux 3 times, add respectively 8 times, 6 times, 6 times at every turn, filter decompression filtrate recycling ethanol.Be recycled to without ethanol taste, 7 ℃ of left and right cold preservations of concentrated solution 48 hours, suck upper strata oils and fats with filter paper, subnatant is centrifugal, centrifugal liquid concentrating under reduced pressure, dry, pulverizing, be American-cockroach-extract, and the small active peptides wherein containing in every gram of extract is 186mg.
Embodiment 3
By 0.5% chlorhexidine gluconate, 18% glycerol and 1.0% castor oil hydrogenated join in 5.0% small active peptides, and agitating heating is dissolved, after mix homogeneously, stop adding 3000ml purified water after heating, in the time that temperature is down to 20 ℃, add 0.013% Mint Essence and 0.05% scented rice essence, after stirring and evenly mixing, cross 0.45 μ m microporous filter membrane, filtrate is added purified water to fill after 4000ml, every bottle of 15ml, after electromagnetic induction sealing, at 95 ℃, moist heat sterilization 30 minutes, to obtain final product.
The preparation method of above-mentioned small active peptides is:
Take periplaneta americana 1000g, add 70% alcohol reflux 3 times, add respectively 8 times, 6 times, 6 times at every turn, filter decompression filtrate recycling ethanol.Be recycled to without ethanol taste, 2 ℃ of left and right cold preservations of concentrated solution 72 hours, suck upper strata oils and fats with filter paper, subnatant is centrifugal, centrifugal liquid concentrating under reduced pressure, dry, pulverizing, be American-cockroach-extract, and the small active peptides wherein containing in every gram of extract is 181mg.
Embodiment 4
By 0.1% chlorhexidine gluconate, 10% glycerol and 0.1% castor oil hydrogenated join in 1.0% small active peptides, and agitating heating is dissolved, after mix homogeneously, stop adding 7000ml purified water after heating, in the time that temperature is down to 20 ℃, add 0.005% Mint Essence and 0.01% scented rice essence, after stirring and evenly mixing, cross 0.45 μ m microporous filter membrane, filtrate is added purified water to fill after 8000ml, every bottle of 15ml, after electromagnetic induction sealing, at 95 ℃, moist heat sterilization 30 minutes, to obtain final product.
The preparation method of above-mentioned small active peptides is:
Take periplaneta americana 3000g, add 90% alcohol reflux 2 times, add respectively 8 times, 6 times at every turn, filter decompression filtrate recycling ethanol.Be recycled to without ethanol taste, 10 ℃ of left and right cold preservations of concentrated solution 24 hours, suck upper strata oils and fats with filter paper, subnatant is centrifugal, centrifugal liquid concentrating under reduced pressure, dry, pulverizing, be American-cockroach-extract, and the small active peptides wherein containing in every gram of extract is 178mg.
Embodiment 5
By 0.2% chlorhexidine gluconate, 13% glycerol and 0.5% castor oil hydrogenated join in 2.0% small active peptides, and agitating heating is dissolved, after mix homogeneously, stop adding 3000ml purified water after heating, in the time that temperature is down to 30 ℃, add 0.01% Mint Essence and 0.03% scented rice essence, after stirring and evenly mixing, cross 0.45 μ m microporous filter membrane, filtrate is added purified water to fill after 4000ml, every bottle of 15ml, after electromagnetic induction sealing, at 95 ℃, moist heat sterilization 30 minutes, to obtain final product.
The preparation method of above-mentioned small active peptides is:
Take periplaneta americana 2000g, add 80% alcohol reflux 2 times, add respectively 8 times, 6 times at every turn, filter decompression filtrate recycling ethanol.Be recycled to without ethanol taste, 5 ℃ of left and right cold preservations of concentrated solution 36 hours, suck upper strata oils and fats with filter paper, subnatant is centrifugal, centrifugal liquid concentrating under reduced pressure, dry, pulverizing, be American-cockroach-extract, and the small active peptides wherein containing in every gram of extract is 187mg.
Embodiment 6
By 0.6% chlorhexidine gluconate, 18% glycerol and 0.15% castor oil hydrogenated join in 8.0% small active peptides, and agitating heating is dissolved, after mix homogeneously, stop adding 9000ml purified water after heating, in the time that temperature is down to 35 ℃, add 0.015% Mint Essence and 0.07% scented rice essence, after stirring and evenly mixing, cross 0.45 μ m microporous filter membrane, filtrate is added purified water to fill after 10000ml, every bottle of 15ml, after electromagnetic induction sealing, at 95 ℃, moist heat sterilization 30 minutes, to obtain final product.
The preparation method of above-mentioned small active peptides is:
Take periplaneta americana 3000g, add 70% alcohol reflux 3 times, add respectively 8 times, 6 times, 6 times at every turn, filter decompression filtrate recycling ethanol.Be recycled to without ethanol taste, 8 ℃ of left and right cold preservations of concentrated solution 24 hours, suck upper strata oils and fats with filter paper, subnatant is centrifugal, centrifugal liquid concentrating under reduced pressure, dry, pulverizing, be American-cockroach-extract, and the small active peptides wherein containing in every gram of extract is 180mg.
Embodiment 7
By 1.0% chlorhexidine gluconate, 20% glycerol and 2.0% castor oil hydrogenated join in 10% small active peptides, and agitating heating is dissolved, after mix homogeneously, stop adding 7000ml purified water after heating, in the time that temperature is down to 25 ℃, add 0.015% Mint Essence and 0.1% scented rice essence, after stirring and evenly mixing, cross 0.45 μ m microporous filter membrane, filtrate is added purified water to fill after 8000ml, every bottle of 15ml, after electromagnetic induction sealing, at 95 ℃, moist heat sterilization 30 minutes, to obtain final product.
The preparation method of above-mentioned small active peptides is:
Take periplaneta americana 2000g, add 90% alcohol reflux 2 times, add respectively 8 times, 6 times at every turn, filter decompression filtrate recycling ethanol.Be recycled to without ethanol taste, 10 ℃ of left and right cold preservations of concentrated solution 48 hours, suck upper strata oils and fats with filter paper, subnatant is centrifugal, centrifugal liquid concentrating under reduced pressure, dry, pulverizing, be American-cockroach-extract, and the small active peptides wherein containing in every gram of extract is 183mg.
Reference embodiment 1
5% small active peptides, glycerol 15%, castor oil hydrogenated 1.0% Hybrid Heating are dissolved, after stirring, add 800ml purified water, after temperature is cooled to below 40 ℃, add wherein Mint Essence 0.01%, scented rice essence 0.05%, after mix homogeneously, cross 0.45 μ m microporous filter membrane, filtrate is added purified water to fill after 1000ml, every bottle of 15ml, after electromagnetic induction sealing, at 95 ℃, moist heat sterilization 30 minutes, to obtain final product.
The preparation method of above-mentioned small active peptides is:
Take periplaneta americana, add 90% alcohol reflux 3 times, add respectively 8 times, 6 times, 6 times at every turn, filter decompression filtrate recycling ethanol.Be recycled to without ethanol taste, 10 ℃ of left and right cold preservations of concentrated solution 48 hours, suck upper strata oils and fats with filter paper, subnatant is centrifugal, and centrifugal liquid concentrating under reduced pressure, dry, pulverizing, be American-cockroach-extract, contains small active peptides at 196mg in every gram of extract.
Reference embodiment 2
Chlorhexidine gluconate 0.45%, glycerol 15%, castor oil hydrogenated 1.0% Hybrid Heating are dissolved, after stirring, add 800ml purified water, after temperature is cooled to below 40 ℃, add wherein Mint Essence 0.01%, scented rice essence 0.05%, after mix homogeneously, cross 0.45 μ m microporous filter membrane, filtrate is added purified water to fill after 1000ml, every bottle of 15ml, after electromagnetic induction sealing, at 95 ℃, moist heat sterilization 30 minutes, to obtain final product.
The screening of antibacterial composition chlorhexidine gluconate concentration range in experimental example 1 formula
1. the fungistatic effect when object of this experimental example is to investigate same antibacterial variable concentrations and the zest to nasal cavity, the antibacterial of wherein said investigation is chlorhexidine gluconate.
2. staphylococcus aureus, escherichia coli, Candida albicans are inoculated in respectively in the nutrient broth medium of having handled well, cultivate after 18 hours, in each culture medium, add the pharmaceutical preparation of the chlorhexidine gluconate that contains variable concentrations of being made by the method in embodiment 1, continue to be cultured to after 48 hours the kill situation of the chlorhexidine gluconate under observation variable concentrations to staphylococcus aureus, escherichia coli, Candida albicans.
Result is as table 1:
| Concentration % | 0.2 | 0.25 | 0.3 | 0.35 | 0.4 | 0.45 | 0.5 | 0.55 |
| Chlorhexidine gluconate | --- | -- | - | - | Qualified | Qualified | Qualified | Qualified |
Note: the fewer expression fungistatic effect of number of "-" is better, another fungistatic effect test detects as staphylococcus aureus, escherichia coli, Candida albicans are killed and reached more than 90% for qualified.
3. adopt the pharmaceutical preparation of the chlorhexidine gluconate that contains variable concentrations that the method in embodiment 1 makes, be sprayed directly on to nasal cavity inside, its different glucose acid chlorhexidine to the zest of nasal cavity as table 2:
| Concentration % | 0.4 | 0.45 | 0.5 | 0.55 |
| Chlorhexidine gluconate | ? | ? | + | ++ |
Note: the number of "+" more multilist shows that chlorhexidine gluconate is larger to the zest of nasal cavity.
The concentration range that considers preferred chlorhexidine gluconate by the result in table 1 and table 2 is at 0.3%-0.5%.The concentration of optimum chlorhexidine gluconate is 0.45%.
The therapeutical effect of experimental example 2 pharmaceutical composition of the present invention to rat contingency rhinitis
1. laboratory animal
100 of SPF level rats, male and female half and half, body weight 200g ± 20g(is provided by Da Shuo bio tech ltd, Chengdu), the quality certification number: SCXK(river) 2013-24.
2. experiment material
Ovalbumin (ovalbumin, OVA) (Sigma company, the U.S.); Aluminium hydroxide (Chengdu Ke Long reagent company limited).
3. medicament sources
Medicament sources in this experiment is in the made pharmaceutical preparation of method of above-described embodiment 1 and reference embodiment 1-2.
4. specific experiment method
4.1 modelling
100 SD rat adaptabilities are raised 1 week, are divided into blank group and modeling group, 12 of blank groups, 88 of modeling groups.Modeling group contingency rhinitis (allergic rhinitis, AR) Establishment of Rat Model concrete steps are as follows: the 1. basic sensitization stage: OVA0.3mg oralbumin and aluminium hydroxide 30mg are that adjuvant adds normal saline 1mL and is mixed into suspension, modeling group is carried out basic sensitization by 1mL/ lumbar injection, the next day once, totally 7 times.2. strengthen the sensitization stage: after basic sensitization completes, with 3%OVA normal saline solution collunarium, every side 50 μ l, carry out nasal cavity for 1 time and excite, continuous application 7 days every day.After each attack, all observe 30min, content comprises sneeze, turns nose, watery nasal discharge etc., records rat behavior and learns point, remembers total score by the standard addition method, and every Mus total score exceedes 5 and is divided into modeling successfully.Blank group matched group adopts AR 1mL/ intraperitoneal injection of saline for rat molding method, the next day once, totally 7 times; Every side 50 μ l continuous normal saline collunarium 7 days.Standards of grading are in table 3
Table 3 rat AR symptom grade scale
4.2 include in and exclusion standard
Inclusive criteria: record rat behavior and learn point, every rat exceedes 5 points and nasal smear and sees that a large amount of eosinophilic granulocytes are modeling success.Exclusion standard: learn 5 points of point < or nasal smear of rat behavior has no a large amount of eosinophilic granulocytes and be modeling failure.88 rats of modeling group have 60 modeling successes.
4.3 experiment grouping and medications
4.3.1 experiment grouping
12 of blank groups, are divided into model control group, administration group 1, administration group 2, administration group 3 by 60 rats of modeling group at random according to body weight, every group each 15.
4.3.2 medication
SD rat in administration group 1 is sprayed nose with the pharmaceutical preparation of making in reference embodiment 1, SD rat in administration group 2 is sprayed nose with the pharmaceutical preparation of making in reference embodiment 2, SD rat in administration group 3 is sprayed nose with the pharmaceutical preparation of making in embodiment 1, every day 2 times, each 100 μ l, continuous 14 days; Blank group and modeling group are sprayed nose by physiologic saline for substitute, every day 2 times, continuous 14 days.
4.4 experimental index
Each group rat was last spray nose after 24 hours, with the capable lumbar injection of 10% chloral hydrate 300mg/kg, after anesthesia, cervical vertebra dislocation is put to death, and opens rapidly bridge of the nose, gets mucous membrane of nasal septum, fix with 10% neutral formalin solution, paraffin embedding, conventional section, adopts hematoxylin-eosin (HE) dyeing, observe and the interior eosinophilic granulocyte (eosinophile, EOS) of digit's area nasal mucosa; After alcian blue-PAS (alcian blue-periodic acid Schiff, AB-PAS) dyeing, the intraepithelial goblet cell number of counting mucous membrane of nasal septum basement membrane (representing individual/cm with goblet cell number in the corresponding epithelial cell of every millimeter of basement membrane).
4.5 experimental result
In each group, in the corresponding epithelial cell of unit are nasal mucosa eosinophilic granulocyte's (EOS) number and every millimeter of basement membrane, goblet cell number represents with mean ± s, and result is as table 4:
Note: with the comparison of blank group, # represents p < 0.5; With model control group comparison, * represents p < 0.05.EOS changes: from count results, model control group EOS quantity is significantly higher than three administration groups; After intranasal steroid count action, administration group EOS number is starkly lower than model control group.
Goblet cell change: from count results, the goblet cell of three administration groups is obviously less than model control group (P < 0.05), and compared with blank group difference not statistically significant.
As seen from Table 4, use the pharmaceutical preparation that the method for a kind of embodiment makes to be obviously better than reference embodiment 1 and reference embodiment 2 using of rhinitis for the treatment of.
In sum, a kind of pharmaceutical composition that is used for the treatment of rhinitis described in the present invention, has the effect of clean nasal cavity, prevention and treatment rhinitis.In air pollution serious today, the rhinitis patient's of each age level sickness rate is more and more higher, the medicament of oral medication rhinitis its curative effect after liver first-pass effect reduces greatly, therefore the pharmaceutical preparation that directly acts on nasal cavity disease sites is more and more subject to rhinitis patient's needs, so the pharmaceutical composition for the treatment of rhinitis of the present invention has wide market prospect.
Claims (8)
1. treat a pharmaceutical composition for rhinitis, it is characterized in that this pharmaceutical composition comprises small active peptides and chlorhexidine gluconate.
2. pharmaceutical composition according to claim 1, it is characterized in that, the constituent of this pharmaceutical composition is take mass volume ratio as small active peptides 1.0%～10.0%, chlorhexidine gluconate 0.1%～1.0%, glycerol 10%～20%, castor oil hydrogenated 0.1%～2.0%, Mint Essence 0.005%～0.015%, scented rice essence 0.01%～0.1%.
3. pharmaceutical composition according to claim 1, it is characterized in that, the constituent of this pharmaceutical composition is take mass volume ratio as small active peptides 2.0%～8.0%, chlorhexidine gluconate 0.2%～0.6%, glycerol 13%～18%, castor oil hydrogenated 0.5%～0.15%, Mint Essence 0.01%～0.015%, scented rice essence 0.03%～0.07%.
4. pharmaceutical composition according to claim 1, it is characterized in that, the constituent of this pharmaceutical composition is take mass volume ratio as small active peptides 3.0%～5.0%, chlorhexidine gluconate 0.3%～0.5%, glycerol 15%～18%, castor oil hydrogenated 0.6%～1.0%, Mint Essence 0.01%～0.013%, scented rice essence 0.03%～0.05%.
5. pharmaceutical composition according to claim 1, it is characterized in that, the constituent of this pharmaceutical composition is take mass volume ratio as small active peptides 3.0%, chlorhexidine gluconate 0.45%, glycerol 15%, castor oil hydrogenated 1.0%, Mint Essence 0.01%, scented rice essence 0.05%.
6. derive from American-cockroach-extract according to the small active peptides described in claim 1-5, its preparation process is as follows: take periplaneta americana, add alcohol reflux 2-3 time of 70-90%, add respectively 8 times, 6 times, 6 times at every turn, filter decompression filtrate recycling ethanol; Be recycled to without ethanol taste, concentrated solution 2-10 ℃ of cold preservation 24-48 hour, sucks upper strata oils and fats with filter paper, subnatant is centrifugal, centrifugal liquid concentrating under reduced pressure, dry, pulverizing, be American-cockroach-extract, in every gram of extract, contains small active peptides more than 160mg.
7. according to the pharmaceutical composition described in claim 1-6, it is characterized in that, is to prepare by the following method:
(1) in the small active peptides of formula ratio, add corresponding chlorhexidine gluconate, glycerol and castor oil hydrogenated, heated and stirred stops heating after making it to dissolve and mixing;
(2) in the mixture obtaining in step (1), add appropriate purified water, thing temperature to be mixed adds Mint Essence and scented rice essence after dropping to 20 ℃～40 ℃, after stirring and evenly mixing, crosses 0.45 microporous filter membrane, gets filtrate;
(3) to certain volume, carry out fill to adding purified water in the filtrate obtaining in step (2), after electromagnetic induction sealing, at 95 ℃, moist heat sterilization 30 minutes, to obtain final product.
8. according to the pharmaceutical composition described in claim 1-7, it is characterized in that, this pharmaceutical composition is applicable to the crowds such as nasal obstruction that acute or chronic rhinitis, allergic rhinitis, sinusitis, flu etc. cause, turbid nasal discharge, sneeze, headache, hyposmia, dry nasal cavity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410125537.0A CN103893741A (en) | 2014-03-31 | 2014-03-31 | Medicine composition for treating rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410125537.0A CN103893741A (en) | 2014-03-31 | 2014-03-31 | Medicine composition for treating rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103893741A true CN103893741A (en) | 2014-07-02 |
Family
ID=50985525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410125537.0A Pending CN103893741A (en) | 2014-03-31 | 2014-03-31 | Medicine composition for treating rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103893741A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108159137A (en) * | 2018-02-13 | 2018-06-15 | 云南诺漫斯生物科技有限公司 | The ointment for treating rhinitis and preparation method of a kind of active constituent containing American cockroach |
| CN112294789A (en) * | 2020-10-15 | 2021-02-02 | 郑涛 | Compound preparation for preventing and treating respiratory tract infection and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526661A (en) * | 2011-12-23 | 2012-07-04 | 蚌埠丰原涂山制药有限公司 | Traditional Chinese medicine composition for treating allergic rhinitis and preparation method thereof |
| CN103127147A (en) * | 2011-11-30 | 2013-06-05 | 天津金耀集团有限公司 | Medicine composition containing budesonide and nitric oxide synthase (NOS) inhibitor and for treating nose inflammation |
| CN103285028A (en) * | 2013-05-14 | 2013-09-11 | 陈美儿 | Composite antibacterial agent of chitosan and organosilicone quaternary ammonium salt and preparation method of composite antibacterial agent |
-
2014
- 2014-03-31 CN CN201410125537.0A patent/CN103893741A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127147A (en) * | 2011-11-30 | 2013-06-05 | 天津金耀集团有限公司 | Medicine composition containing budesonide and nitric oxide synthase (NOS) inhibitor and for treating nose inflammation |
| CN102526661A (en) * | 2011-12-23 | 2012-07-04 | 蚌埠丰原涂山制药有限公司 | Traditional Chinese medicine composition for treating allergic rhinitis and preparation method thereof |
| CN103285028A (en) * | 2013-05-14 | 2013-09-11 | 陈美儿 | Composite antibacterial agent of chitosan and organosilicone quaternary ammonium salt and preparation method of composite antibacterial agent |
Non-Patent Citations (4)
| Title |
|---|
| 程福亮等: "抗菌肽生物活性及其影响因素的研究进展", 《中国生物制品学杂志》 * |
| 罗以勤等: "小分子活性肽筛选方法", 《生命的化学》 * |
| 郭美丽等: "生物活性肽胶囊对实验小鼠增强免疫力功能的影响", 《中国卫生检验杂志》 * |
| 陶学勇等: "功能性鼻内窥镜术后康复新鼻腔冲洗疗效观察", 《中国民康医学》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108159137A (en) * | 2018-02-13 | 2018-06-15 | 云南诺漫斯生物科技有限公司 | The ointment for treating rhinitis and preparation method of a kind of active constituent containing American cockroach |
| CN112294789A (en) * | 2020-10-15 | 2021-02-02 | 郑涛 | Compound preparation for preventing and treating respiratory tract infection and application thereof |
| CN112294789B (en) * | 2020-10-15 | 2022-06-07 | 郑涛 | Compound preparation for preventing and treating respiratory tract infection and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014359488B2 (en) | Ionic aqueous compositions | |
| CN104488986A (en) | Traditional Chinese medicine sterilizing liquid for clinical laboratory | |
| CN101475626B (en) | Method for extracting transfer factor from pig spleen | |
| KR20170022343A (en) | Prevention, improvement of skin allergy agent based on lactic acid, floral water and medicinal herb extract | |
| CN103735581A (en) | Care solution for cleaning nasal cavity and preparation method of care solution | |
| CN104548093A (en) | Composition for treating piglet diarrhea and preparation method of composition | |
| CN103893741A (en) | Medicine composition for treating rhinitis | |
| CN104997917A (en) | Gynecological traditional Chinese medicine composition containing nano-silver | |
| CN103355675B (en) | Composition with lung clearing function and preparation method | |
| CN103505540A (en) | Oil-in-water compound cedar oil nano emulsion composition | |
| CN103083658B (en) | A kind of vaccine adjuvant composition being used for the treatment of or preventing pig infectious disease | |
| CN103877561A (en) | Pharmaceutical composition containing small-molecular active peptides | |
| CN101948537B (en) | Method for extracting chicken yolk antibody against infectious bursal disease | |
| WO2017193509A1 (en) | Bionic gynecological lotion and preparation method therefor | |
| CN113476318A (en) | Organic mica antibacterial composition, oral cleaning and nursing product, and preparation method and application thereof | |
| KR20220067974A (en) | Composition for anti-allergy comprising extract of forsythia velutina | |
| CN103750097B (en) | Containing the bee glue honeyed paste and preparation method thereof of honeysuckle elite | |
| CN105077263A (en) | Medicinal and edible sea cucumber polypeptide as well as preparation method and application thereof | |
| CN101759770A (en) | Method for extracting transfer factor from chicken spleen | |
| CN104800253A (en) | Use of eurycoma longifolia extract | |
| CN103751230A (en) | Application of gingko extract nanometer liposome in gynecological disease treatment | |
| CN102631474A (en) | Nano emulsion for treating anaerobic infections of intestinal tracts of livestocks and preparation method of nano emulsion | |
| RU2323735C1 (en) | Agent for treatment and prevention of sexually transmitted diseases, and method of its preparation | |
| CN106668635A (en) | Novel application of xiao'er qixingcha | |
| CN103931672A (en) | Antibacterial sterilizing skin disinfectant liquid and antibacterial sterilizing antiseptic disinfector and preparation methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140702 |